

US008889894B2

# (12) United States Patent Baird et al.

# (54) COMPOUNDS FOR USE IN THERAPY

 (75) Inventors: Mark Stephen Baird, Gwynedd (GB); Juma' a Raheem Najeem
 Al-Dulayy-mi, Gwynedd (GB);
 Cornelias Theunissen, Gwynedd (GB);
 Gani Koza, Gwynedd (GB); Seppe
 Vander-Beken, Ghent (BE); Johan
 Adriaan Marc Grooten, Ghent (BE)

(73) Assignees: **Bangor University**, Gwynedd (GB); **Universiteit Gent**, Ghent (BE)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 645 days.

(21) Appl. No.: 12/988,235

(22) PCT Filed: Apr. 22, 2009

(86) PCT No.: **PCT/GB2009/050408** 

§ 371 (c)(1),

(2), (4) Date: Mar. 3, 2011

(87) PCT Pub. No.: WO2009/130506
PCT Pub. Date: Oct. 29, 2009

(65) Prior Publication Data
US 2011/0150981 A1 Jun. 23, 2011

## (30) Foreign Application Priority Data

Apr. 22, 2008 (GB) ...... 0807305.8

(51) **Int. Cl.** *C07C 59/185* (2006.01) *C07C 61/04* (2006.01)

(Continued)

(Continued)

(10) Patent No.: US 8,889,894 B2

(45) **Date of Patent:** Nov. 18, 2014

# (58) Field of Classification Search

None

See application file for complete search history.

#### (56) References Cited

#### U.S. PATENT DOCUMENTS

2007/0027098 A1 2/2007 Raz et al.

## OTHER PUBLICATIONS

Yuan, Y., et al., A common mechanism for the biosynthesis of methoxya nd cyclopropyl mycolic acids in *Mycobacterium tuberculosis*, Nov. 1996, Proc.Natl. Acad. Sci. USA, vol. 93, pp. 12828-1833 \*

#### (Continued)

Primary Examiner — Yate K Cutliff (74) Attorney, Agent, or Firm — Norris McLaughlin & Marcus PA

### (57) ABSTRACT

A compound of formula (I) for use in the treatment of a disease of the immune system; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms;  $\mathbf{R}^1$  is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 40 carbon atoms; each of  $\mathbf{R}^2$ ,  $\mathbf{R}^3$  and  $\mathbf{R}^4$  is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, arylalkylene or alkylarylene moiety having from 1 to 40 carbon atoms; each of X, Y and Z is independently selected from an optionally-substituted alkylene, alkenylene, alkenylene, arylene, arylene, alkylarylene, eycloalkylene, ketone, ester, amide, imide, imine, thioether, ether, thioester and thioketone; and P is selected from hydrogen, an alkyl group, a sugar residue, or a metal, phosphonium or ammonium species; wherein at least one of X, Y and Z includes a moiety selected from cyclopropyl, C=A, C-AH and C—OR5; wherein  $\mathbf{R}^5$  is alkyl or haloalkyl, and A is O, S or  $\mathbf{NR}^6$ , wherein  $\mathbf{R}^6$  may be H or 20 alkyl.



